RNA therapeutics are moving fast. This concise summary captures what leaders are watching now—and the practical moves biotechs can make to reach milestones sooner.
Inside the report
- Where mRNA, siRNA, and ASOs are (really) heading next—and why it matters for near-term program decisions.
- The shift from delivery-only thinking to delivery and chemistry, with implications for targets beyond the liver.
- What it takes to scale to prevalent diseases: smarter design, cost curves, and manufacturing considerations.
- How to de-risk global development with the right country mix, regulatory pathways, and site networks.
- Where specialized partners accelerate start-up, enrollment, and operational quality.
Get the takeaways in minutes.